➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,530,668

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,530,668
Title:Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
Abstract: An optically active 4-phenylthiazole derivative having a thrombopoietin receptor agonist activity and a pharmaceutical composition containing the present compound as an active ingredient are created, and a platelet production regulating agent which can be orally administered is provided. Disclosed is a pharmaceutical composition containing, as an active ingredient, an optically active compound represented by the formula: ##STR00001## wherein, R.sup.1 is a halogen atom or C1-C3 alkyloxy; R.sup.2 is C1-C8 alkyl; R.sup.3 is C1-C8 alkyl; R.sup.4 and R.sup.5 are each independently a fluorine atom or chlorine atom; R.sup.6 is C1-C3 alkyl or C1-C3 alkyloxy; * indicates that a carbon atom marked with an asterisk is an asymmetric carbon, a pharmaceutically acceptable salt thereof, or a solvate thereof.
Inventor(s): Takayama; Masami (Osaka, JP), Kurose; Noriyuki (Osaka, JP)
Assignee: Shionogi & Co., Ltd. (Osaki-Shi, Osaka, JP)
Application Number:12/671,476
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,530,668

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Shionogi Inc MULPLETA lusutrombopag TABLET;ORAL 210923-001 Jul 31, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,530,668

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2007-198590Jul 31, 2007
PCT Information
PCT FiledJuly 29, 2008PCT Application Number:PCT/JP2008/063541
PCT Publication Date:February 05, 2009PCT Publication Number: WO2009/017098

International Family Members for US Patent 8,530,668

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2008283357   Start Trial
Brazil PI0814891   Start Trial
Canada 2694567   Start Trial
China 101809008   Start Trial
China 103393678   Start Trial
China 103396313   Start Trial
China 103450110   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.